In PC subsets, IFNβ-induced upregulation of NAD + -consuming enzymes PARP9, PARP10, and PARP14 enhances tumor sensitivity to nicotinamide phosphoribosyltransferase inhibitors (Moore et al., 2021). Here, PARP9 is linked to pachyonychia congenita.